Functional Analysis of the Arg91GIn Substitution in the Factor VIII Binding Domain of von Willebrand Factor Demonstrates Variable Phenotypic Expression
- 1 April 1993
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 70 (04) , 691-696
- https://doi.org/10.1055/s-0038-1649651
Abstract
Summary: An Arg91Gln substitution in the mature von Willebrand factor (vWF) has been associated with defective binding of vWF to factor VIII (FVIII). We studied four families with members initially classified as having type I von Willebrand disease (vWD) who were either homozygous or heterozygous for the Arg91Gln change. The first family was the original case described by Nishino et al. (1) where three members were homozygous for the Gln91 allele. They had a low FVIII coagulant activity:vWF antigen (VIIIC:vWFAg) ratio, from 0.29 to 0.44, and the ability of their plasma vWF to bind FVIII was markedly decreased. All the heterozygous members had normal vWF and FVIII levels but the capacity of their plasma vWF to bind FVIII was reduced and intermediate between the homozygous members and normals. The affected individual from the second family was heterozygous for the Gln91 allele and demonstrated a VIIIC:vWFAg ratio of 0.98. The FVIII binding assay confirmed the heterozygous status indicating that the moderately low levels of vWF were due to reduced expression of both alleles. The propositus from the third family was also heterozygous and had below normal levels of vWF as well as a low VIIIC:vWFAg ratio of 0.34; however, FVIII binding to her plasma vWF was similar to that of the homozygous individuals suggesting that Gln91-vWF was the major circulating form. Her daughter who has type I vWD inherited the allele without the Gln91 mutation indicating that the expression of this allele was indeed impaired. The heterozygous patient in the fourth family had a vWF level of 24 U/dl but an VIIIC:vWFAg ratio greater than 2. Her plasma vWF showed normal FVIII binding implying that the Gln91 mutation was linked to a defect that repressed the expression of the allele. The Arg91Gln substitution appears to decrease but not eradicate FVIII binding suggesting a critical concentration of vWF be attained before the defect becomes phenotypically important.Keywords
This publication has 9 references indexed in Scilit:
- A Database of Polymorphisms in the von Willebrand Factor Gene and PseudogeneThrombosis and Haemostasis, 1993
- Comparison of the primary structure of the functional domains of human and porcine von Willebrand factor that mediate platelet adhesionBiochemical and Biophysical Research Communications, 1992
- Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A.Proceedings of the National Academy of Sciences, 1991
- Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophilia A carriers: consequences for therapy and genetic counsellingBritish Journal of Haematology, 1990
- The effect of von Willebrand factor on activation of factor VIII by factor XaEuropean Journal of Biochemistry, 1990
- Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.Journal of Clinical Investigation, 1988
- Reconstitution of human factor VIII from isolated subunitsArchives of Biochemistry and Biophysics, 1988
- Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's diseaseBritish Journal of Haematology, 1982
- Interaction of factor VIII-von Willebrand Factor with phospholipid vesiclesBiochemical Journal, 1981